DOCSLIB.ORG

Glucocorticoid Regulation of the G-Protein Coupled Estrogen Receptor (GPER) in Mouse Hippocampal Neurons

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glucocorticoid Regulation of the G-Protein Coupled Estrogen Receptor (GPER) in Mouse Hippocampal Neurons Glucocorticoid Regulation of the G-Protein Coupled Estrogen Receptor (GPER) in Mouse Hippocampal Neurons by Kate Colleen Eliza Nicholson A Thesis presented to The University of Guelph In partial fulfilment of requirements for the degree of Master of Science in Biomedical Sciences Guelph, Ontario, Canada © Kate Colleen Eliza Nicholson, August, 2019 ABSTRACT GLUCOCORTICOID REGULATION OF THE G-PROTEIN COUPLED ESTROGEN RECEPTOR (GPER) IN MOUSE HIPPOCAMPAL NEURONS Kate Colleen Eliza Nicholson Advisor: University of Guelph, 2019 Dr. Neil J. MacLusky The most prevalent estrogen, 17β-estradiol, binds the non-classical G-protein coupled estrogen receptor (GPER) with high affinity resulting in rapid activation of the c- jun N terminal kinase (JNK) pathway. GPER activation mediates some of the rapid neurotrophic and memory-enhancing effects of 17β-estradiol in the female hippocampus. However, exposure to stressful stimuli may impair these beneficial effects. This thesis characterizes neurosteroid receptor expression in murine-derived mHippoE cell lines that are subsequently used to investigate the glucocorticoid regulation of GPER protein expression and functional activation. This thesis demonstrates that 24-hour treatment with a glucocorticoid receptor agonist reduces GPER protein expression and activation of JNK in female-derived mHippoE-14s. Using an in vivo model, treatment with glucocorticoids significantly reduces hippocampal activation of JNK in female ovariectomized CD1 mice. Collectively, this thesis uses in vitro and in vivo models to characterize glucocorticoid regulation of GPER expression and signalling in female murine hippocampal neurons. ACKNOWLEDGEMENTS To Dr. MacLusky: I would like to thank you for inspiring my passion for science and pursuit of knowledge. Over the past 2 years, you have provided me with countless opportunities to grow as a young researcher and I am tremendously grateful for this. Your ongoing support, guidance, and encouragement has given me the confidence to share my own thoughts, questions, and opinions with other researchers. You have challenged me to improve my scientific communication and critical thinking skills while inspiring enthusiasm for the implications of our research. This opportunity has been uniquely rewarding and I am so very grateful for your dedication as a mentor. To my advisory committee members, Dr. Bettina Kalisch and Dr. Jon LaMarre: I would like to thank you for your guidance, support, and insight throughout the course of my MSc degree. I feel very fortunate to have been able to approach both of you for friendly advice and opinions in shaping the design and interpretations of this project. To my MacLusky lab parents, Dr. Ari Mendell and Dr. Carolyn Creighton: I would like to sincerely thank you for your ongoing patience in training me while sharing your wisdom and mentorship throughout graduate school. Carolyn, I am very grateful for your kindness while introducing me to the foundations of lab work and research. Ari, thank you for supporting and challenging me to grow as a graduate student. You have always been the calm in the storm and I am incredibly grateful for your leadership and friendship throughout graduate school. I feel very fortunate to have worked alongside inspiring mentors and friends like you two. To my MacLusky lab siblings: E-Marti and Lo-dawg, thank you for being my rocks through it all. Thank you for making fun of me when I deserve it and putting up with me when I don’t. Hayl-storm, Dry Rice Lawton, and E-Craig, thank you for all of the lab chats, support, and humour. To all other MacLusky lab members, thank you for making the long lab days seem shorter. To the faculty and students of the Department of Biomedical Sciences: You have provided me with many rewarding opportunities to grow in and outside of the lab and classrooms. Thank you for making this a welcoming, enriching, and collaborative environment to learn in. Finally, thank you to my family for all of the love, long phone calls, and support while cheering me on throughout the ups and downs of graduate school. Thank you for always reminding me to look at the bigger picture. To my friends, thank you for keeping me grounded with your love, encouragement, humour, and kindness. iii DECLARATION OF WORK PERFORMED I declare that I have performed and completed all of the work presented within this Master of Science thesis, with the exception of the following: All ovariectomy surgical procedures, subcutaneous drug injections, cervical dislocations, and brain extractions in Chapter 5 were performed by Emily Martin (Master of Science candidate supervised by Dr. Neil MacLusky and Dr. Elena Choleris, Department of Psychology, University of Guelph). All Sanger sequencing was performed by the University of Guelph’s Advanced Analysis Centre Genomics facility. iv TABLE OF CONTENTS ABSTRACT ................................................................................................................................ ii ACKNOWLEDGEMENTS .......................................................................................................... iii DECLARATION OF WORK PERFORMED ............................................................................... iv LIST OF TABLES .................................................................................................................... viii LIST OF FIGURES .................................................................................................................... ix LIST OF ABBREVIATIONS ....................................................................................................... xi LIST OF APPENDICES ........................................................................................................... xiv CHAPTER 1: INTRODUCTION AND REVIEW OF THE LITERATURE ..................................... 1 Sex Differences in Neuropsychiatric and Neurodegenerative Disorders ............................ 2 The hippocampus………………………………………………………………………………..……...4 The Hypothalamic-Pituitary-Gonadal (HPG) Axis .................................................................. 6 Steroid and Estradiol Biosynthesis........………………...………………………………………….8 Steroid Receptors ...................................................................................................................13 Estrogen Receptors in the Hippocampus .............................................................................14 Functional Effects of Hippocampal Estrogens and GPER Activation .................................20 Stress and the Hypothalamic-Pituitary-Adrenal (HPA) Axis…………………………………...28 Glucocorticoid Biosynthesis ..................................................................................................30 Glucocorticoid Receptor Activation in the Hippocampus ....................................................31 Functional Effects of GR Activation in the Hippocampus ....................................................31 Stress and Estrogen Interactions in the Hippocampus ........................................................34 Rationale ..................................................................................................................................36 Hypothesis and Objectives ....................................................................................................37 CHAPTER 2: CHARACTERIZATION OF RECEPTOR MRNA EXPRESSION IN MHIPPOE-14 AND HIPPOE-18 IMMORTALIZED HIPPOCAMPAL NEURONS .............................................39 Introduction .............................................................................................................................40 Experimental Procedures .......................................................................................................47 Cell Culture Conditions ......................................................................................................47 RNA Isolation .....................................................................................................................48 Reverse Transcription and cDNA Synthesis .......................................................................48 Conventional Polymerase Chain Reactions and Visualization……………………..…………49 Results .....................................................................................................................................53 Discussion ...............................................................................................................................57 v Conclusion ..............................................................................................................................63 CHAPTER 3: GLUCOCORTICOID REGULATION OF GPER PROTEIN STEADY STATE LEVELS IN MHIPPOE-14 AND MHIPPOE-18 IMMORTALIZED HIPPOCAMPAL NEURONS 65 Introduction .............................................................................................................................66 Experimental Procedures .......................................................................................................68 Chemical and Stock Solutions ............................................................................................68 Cell Culture Conditions ......................................................................................................68 Treatment and Protein Collection .......................................................................................69 Western Blotting.................................................................................................................70
Load more

Recommended publications
  • F=Separate Folder **** F*=Misc Folder Under First Letter(S) **** MF=Fiche
    NORTH JERSEY HISTORY CENTER VERTICAL FILE (HVFG) LIST OF FAMILY NAMES MARCH 1991 REVISED 1995 REVISED 2000 REVISED 2006 REVISED 2012 REVISED 2014 **** F=separate folder **** F*=Misc folder under first letter(s) **** MF=fiche A MF(5) F ALLEN MF ABBEY MF ALLER MF ABBOTT MF ALLERTON MF F* ABEEL MF ALLING s.a. AUBLE/ABLE/ABELL MF F ALLISON MF ABELES F* ALLMAN F* ABELL F* ALLRED F ABER/ABERS F* ALLWOOD MF ABLE see AUBLE F* ALMER F* ABRAHAM MF ALMY/ALMEY MF ACKEN F* ALPAUGH F ACKERLY/AKERLY MF ALVORD MF F* ACKERMAN MF F* ALWARD MF ACKERS F* AMATO MF ACKERSON MF AMBROSE MF F* ACKLEY MF F* AMERMAN/AMMERMAN MF F* ADAIR MF AMES F ADAMS F* AMMANN MF ADAMSON MF F ANDERSON F* ADCOCK F* ANDREASSEN MF ADER MF ANDRES MF ADEY F* ANDREW MF ADRIAENS MF ANDRUS/ANDRUSS/ANDREWS MF AFFLECK F* ANGERBAUER F* AGNELLI MF F* ANGLE F* AHLERS F* ANGUS MF AHRENS F* ANGWIN MF F* AIKMAN MF ANNAN F* AINGE MF ANNIN MF(2) AKERLY MF ANSLEY F* ALBANESE MF F* ANSON F* ALBINSON F* ANSPACH MF ALBRECHT MF ANTES MF F* ALBRIGHT MF(2) F* APGAR MF ALDEN MF F* APPLEGATE/APPLEGET/ MF F* ALEXANDER APPLEGIT MF ALGER MF APPLETON MF ALGIER MF APPLIN F* ALGREW F* ARCH MF ALLABEN MF F* ARCHER MF ALLAIRE F* ARDILL **** F=separate folder **** F*=Misc folder under first letter(s) **** MF=fiche F* ARICO F* BABO F* ARINTAGA MF BABSON F* ARLINGTON MF BACHE MF F* ARMITAGE F* BACKMAN MF ARMOUR MF F* BACON MF F* ARMSTRONG MF BADCOCK F* ARNESTAGE MF BADENHAUSEN MF ARNETT MF F* BADGLEY/BAGLEY MF(3) F ARNOLD MF BAILEY MF ARROWSMITH MF BAIR F* ARTUS MF F* BAIRD F* ASHFIELD MF(3) F BAKER MF ASSHETON F
    [Show full text]
  • Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission
    The Journal of Neuroscience, October 14, 2015 • 35(41):14057–14069 • 14057 Neurobiology of Disease Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission Alexandra Alvarsson,1* Xiaoqun Zhang,1* Tiberiu L Stan,1 Nicoletta Schintu,1 Banafsheh Kadkhodaei,2 Mark J. Millan,3 Thomas Perlmann,2,4 and Per Svenningsson1 1Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, SE-17176 Stockholm, Sweden, 2Ludwig Institute for Cancer Research, SE-17177 Stockholm, Sweden, 3Pole of Innovation in Neuropsychiatry, Institut de Recherches Servier, Centre de Recherches de Croissy, Paris 87290, France, and 4Department of Cell and Molecular Biology, Karolinska Institutet, SE-17177 Stockholm, Sweden Parkinson’s disease (PD) is a movement disorder characterized by a progressive loss of nigrostriatal dopaminergic neurons. Restoration of dopamine transmission by L-DOPA relieves symptoms of PD but causes dyskinesia. Trace Amine-Associated Receptor 1 (TAAR1) modulates dopaminergic transmission, but its role in experimental Parkinsonism and L-DOPA responses has been neglected. Here, we report that TAAR1 knock-out (KO) mice show a reduced loss of dopaminergic markers in response to intrastriatal 6-OHDA administra- tion compared with wild-type (WT) littermates. In contrast, the TAAR1 agonist RO5166017 aggravated degeneration induced by intra- striatal6-OHDAinWTmice.Subchronic L-DOPAtreatmentofTAAR1KOmiceunilaterallylesionedwith6-OHDAinthemedialforebrain bundle resulted in more pronounced rotational behavior and dyskinesia than in their WT counterparts. The enhanced behavioral sensitization to L-DOPA in TAAR1 KO mice was paralleled by increased phosphorylation of striatal GluA1 subunits of AMPA receptors. Conversely, RO5166017 counteracted both L-DOPA-induced rotation and dyskinesia as well as AMPA receptor phosphorylation.
    [Show full text]
  • City of Charleston Municipal Court
    City of Charleston Municipal Court 9/24/2021 Page 1 Officer Court Events - Monday, September 27, 2021 to Friday, October 29, 2021 Excludes Motions, Deferrals, and Jury Trials Adams Christopher Tuesday, October 19, 2021 20210416019558 8:30 am Criminal Bench Trial Manucy, Majorie Disorderly Conduct Katelyn Tuesday, October 12, 2021 20210416028112 9:30 am Criminal Bench Trial Thompson, Peter Shoplifting <= $2,000 - 16 - 13-0110(A) Akins Nicholas Friday, October 1, 2021 20210415996197 8:30 am Criminal Bench Trial Rowland, Kelsi Driving Under Influence 1st Offense . No BA Thursday, October 14, 2021 20210415968789 8:30 am Traffic Bench Trial Steed, Terrell DUS, license not suspended for DUI - 1st offense (56-01-0460)(A)(1)(a) 20210416020632 8:30 am Traffic Bench Trial Hurst, Louis Driving Under Influence 1st Offense . No BA 9/24/2021 Page 2 Officer Court Events - Monday, September 27, 2021 to Friday, October 29, 2021 Excludes Motions, Deferrals, and Jury Trials Akins Nicholas Thursday, October 14, 2021 20210416023954 8:30 am Traffic Bench Trial Connolly, Colin Operating vehicle w/o reg and license due to delinquency - 56-03-0840 20210416024511 8:30 am Traffic Bench Trial Marsh, Joshua Driving Under Influence 1st Offense . No BA 8102P0769552 8:30 am Traffic Bench Trial Simmons, Jamaul DUS, license not suspended for DUI - 1st offense (56-01-0460)(A)(1)(a) Friday, October 15, 2021 20210415961061 8:30 am Criminal Bench Trial-GATEWAY INCOMPLETE Gardo, Joshua Public Drunk 20210416024512 8:30 am Criminal Bench Trial Lowe, Zackary Malicious Injury to animals, personal property, injury value $2,000 or less 20210416024513 8:30 am Criminal Bench Trial Lowe, Zackary Careless Driving Monday, October 18, 2021 20210415989747 9:00 am DUI Pre-Trial Hearing Rotibi, Katari Driving Under Influence >= .10% <.16% with BA 56-05-2930(B) 20210416013897 9:00 am DUI Pre-Trial Hearing McClelland, Bradley Driving Under Influence 1st Offense .
    [Show full text]
  • Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System
    International Journal of Molecular Sciences Review Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System Shenglong Zou and Ujendra Kumar * Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-604-827-3660; Fax: +1-604-822-3035 Received: 9 February 2018; Accepted: 11 March 2018; Published: 13 March 2018 Abstract: The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediated by two members of the G-protein coupled receptor family, cannabinoid receptors 1 (CB1R) and 2. The CB1R is the prominent subtype in the central nervous system (CNS) and has drawn great attention as a potential therapeutic avenue in several pathological conditions, including neuropsychological disorders and neurodegenerative diseases. Furthermore, cannabinoids also modulate signal transduction pathways and exert profound effects at peripheral sites. Although cannabinoids have therapeutic potential, their psychoactive effects have largely limited their use in clinical practice. In this review, we briefly summarized our knowledge of cannabinoids and the endocannabinoid system, focusing on the CB1R and the CNS, with emphasis on recent breakthroughs in the field. We aim to define several potential roles of cannabinoid receptors in the modulation of signaling pathways and in association with several pathophysiological conditions. We believe that the therapeutic significance of cannabinoids is masked by the adverse effects and here alternative strategies are discussed to take therapeutic advantage of cannabinoids. Keywords: cannabinoid; endocannabinoid; receptor; signaling; central nervous system 1. Introduction The plant Cannabis sativa, better known as marijuana, has long been used for medical purpose throughout human history.
    [Show full text]
  • Surname Given Maiden Name Age Date Page Abblett Fred, D. (Sr.) 65 October Ll, L949 5 Abel Infant Infant November 6, L949 2
    Surname Given Maiden Name Age Date Page Abblett Fred, D. (Sr.) 65 October ll, l949 5 Abel infant infant November 6, l949 2 Abrahamson Sholom (Sam) 60 August 8, l949 2 Abrudan Nicholas 73 April 3, l949 26 Acton John Wesley (Jr.) l7 December 8, l949 2 Adamczyk Thomas 59 20-Jan-49 Adamczyk Thomas 58 23-Jan-49 Adams Cecil, A. 39 January 3l, l949 Adams Ida, C. 84 January 24, l949 Adler Joseph, T. (Capt.) 58 July 26, l949 2 Agardi Sara 78 July 5, l949 2 Ahlborn John, F. 59 May 22, l949 2 Ahlering Edward, L. 46 December 29, 2 l949 Aiken Martha May 20, l949 2 Ainsworth Sidney 66 June 23, l949 l5 Ajerski John, M. 72 7-Jan-49 Akers William Eugene 2 20-Feb-49 Albertson Theron, R. l4 September l3, 2 l949 Alex Charles 58 November 2, l949 2 Alexander Esther Harrison 55 September 20, 2 l949 Alexander Harry 52 October 7, l949 2 Alexanderson Cecelia 5l April ll, l949 2 Alexanderson Charles, G. (Pfc.) 30 May 5, l949 2 Allie Sam 59 May 20, l949 2 Alonzo Elsie 37 May 2, l949 2 Alt Anna 75 December 2l, 2 l949 Amrai Joseph (Sr.) 64 July 3, l949 2 Anderson Catherine 8l October 4, l949 l7 Anderson Celia 9 June l, l949 9 Anderson Elizabeth 72 September l4, 2 l949 Anderson Oliver, A. September 22, 2 l949 Andree G.W. (Dr.) 43 October 7, l949 2 Andrews Oliver (Sr.) 80 April 4, l949 l3 Andriso Margaret, E. 34 November 25, 33 l949 Anglin M.L.
    [Show full text]
  • Targeting Lysophosphatidic Acid in Cancer: the Issues in Moving from Bench to Bedside
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by IUPUIScholarWorks cancers Review Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside Yan Xu Department of Obstetrics and Gynecology, Indiana University School of Medicine, 950 W. Walnut Street R2-E380, Indianapolis, IN 46202, USA; [email protected]; Tel.: +1-317-274-3972 Received: 28 August 2019; Accepted: 8 October 2019; Published: 10 October 2019 Abstract: Since the clear demonstration of lysophosphatidic acid (LPA)’s pathological roles in cancer in the mid-1990s, more than 1000 papers relating LPA to various types of cancer were published. Through these studies, LPA was established as a target for cancer. Although LPA-related inhibitors entered clinical trials for fibrosis, the concept of targeting LPA is yet to be moved to clinical cancer treatment. The major challenges that we are facing in moving LPA application from bench to bedside include the intrinsic and complicated metabolic, functional, and signaling properties of LPA, as well as technical issues, which are discussed in this review. Potential strategies and perspectives to improve the translational progress are suggested. Despite these challenges, we are optimistic that LPA blockage, particularly in combination with other agents, is on the horizon to be incorporated into clinical applications. Keywords: Autotaxin (ATX); ovarian cancer (OC); cancer stem cell (CSC); electrospray ionization tandem mass spectrometry (ESI-MS/MS); G-protein coupled receptor (GPCR); lipid phosphate phosphatase enzymes (LPPs); lysophosphatidic acid (LPA); phospholipase A2 enzymes (PLA2s); nuclear receptor peroxisome proliferator-activated receptor (PPAR); sphingosine-1 phosphate (S1P) 1.
    [Show full text]
  • Classified Personnel List University of Oregon
    CLASSIFIED PERSONNEL LIST UNIVERSITY OF OREGON Employees on Record as of November 1, 2016 CLASSIFIED PERSONNEL are employees represented by the Service Employees International Union (SEIU), Local 503 and the Teamsters Union, Local 206, and temporary employees (support staff who typically work less than six months, sometimes as seasonal employees). NOTE: An employee can have more than one job, but may not be receiving pay from all jobs. JOB TYPE: The type of job the employee holds. A primary job is the employee’s main job; a secondary job is an additional job; and an overload job reflects additional duties or stipends. JOB STATUS: The status of the job; active, on leave, or terminated. An active or on leave job may or may not be receiving pay; the job may be waiting to be terminated by the department. JOB START DATE: The date the job originally started. Dates before the implementation of the HR Information System in January of 1999 will reflect the date in 1998 that the existing job was established in the new system. This date is not changed when a job is reactivated after a summer leave. JOB END DATE: The date the job currently ends. This date may be extended if the job is extended. HOME DEPARTMENT: The department for the employee’s primary job. JOB TITLE: The title of the employee's job. An employee may hold more than one job and thus, may have more than one job title. PAY DEPARTMENT: The department responsible for time entry for the employee in a particular job.
    [Show full text]
  • CB1 and GPR55 Receptors Are Co-Expressed and Form Heteromers in Rat 3 and Monkey Striatum
    YEXNR-11769; No. of pages: 9; 4C: Experimental Neurology xxx (2014) xxx–xxx Contents lists available at ScienceDirect Experimental Neurology journal homepage: www.elsevier.com/locate/yexnr 1 Regular Article 2 CB1 and GPR55 receptors are co-expressed and form heteromers in rat 3 and monkey striatum 4 E. Martínez-Pinilla a,⁎, I. Reyes-Resina e, A. Oñatibia-Astibia a,M.Zamarbidea,A.Ricobarazad,G.Navarroe, 5 E. Moreno e,I.G.Dopeso-Reyesb,c, S. Sierra b,c, A.J. Rico b,c,E.Rodab,c,J.L.Lanciegob,c,1,R.Francoa,e,1 6 a Laboratory of Cell and Molecular Neuropharmacology, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain 7 b Laboratory of Basal Ganglia Neuroanatomy, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain 8 c Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain 9 d Laboratoire de Plasticité du Cerveau, ESPCI-ParisTech, Paris, France 10 e Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, Spain 11 article info abstract 12 Article history: Heteromerization of G-protein-coupled receptors is an important event as they integrate the actions 22 13 Received 6 May 2014 of extracellular signals to give heteromer-selective ligand binding and signaling, opening new ave- 23 14 Revised 13 June 2014 nues in the development of potential drug targets in pharmacotherapy. A further aim of the present 24 15 Accepted 17 June 2014 paper was to check for cannabinoid CB –GPR55 receptor heteromers in the central nervous system 25 16 Available online xxxx 1 (CNS), specifically in striatum.
    [Show full text]
  • Metabolite Sensing Gpcrs: Promising Therapeutic Targets for Cancer Treatment?
    cells Review Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment? Jesús Cosín-Roger 1,*, Dolores Ortiz-Masia 2 , Maria Dolores Barrachina 3 and Sara Calatayud 3 1 Hospital Dr. Peset, Fundación para la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO, 46017 Valencia, Spain 2 Departament of Medicine, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain; [email protected] 3 Departament of Pharmacology and CIBER, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain; [email protected] (M.D.B.); [email protected] (S.C.) * Correspondence: [email protected]; Tel.: +34-963851234 Received: 30 September 2020; Accepted: 21 October 2020; Published: 23 October 2020 Abstract: G-protein-coupled receptors constitute the most diverse and largest receptor family in the human genome, with approximately 800 different members identified. Given the well-known metabolic alterations in cancer development, we will focus specifically in the 19 G-protein-coupled receptors (GPCRs), which can be selectively activated by metabolites. These metabolite sensing GPCRs control crucial processes, such as cell proliferation, differentiation, migration, and survival after their activation. In the present review, we will describe the main functions of these metabolite sensing GPCRs and shed light on the benefits of their potential use as possible pharmacological targets for cancer treatment. Keywords: G-protein-coupled receptor; metabolite sensing GPCR; cancer 1. Introduction G-protein-coupled receptors (GPCRs) are characterized by a seven-transmembrane configuration, constitute the largest and most ubiquitous family of plasma membrane receptors, and regulate virtually all known physiological processes in humans [1,2]. This family includes almost one thousand genes that were initially classified on the basis of sequence homology into six classes (A–F), where classes D and E were not found in vertebrates [3].
    [Show full text]
  • Activation of Dorsal Horn Cannabinoid CB2 Receptor Suppresses The
    Niu et al. Journal of Neuroinflammation (2017) 14:185 DOI 10.1186/s12974-017-0960-0 RESEARCH Open Access Activation of dorsal horn cannabinoid CB2 receptor suppresses the expression of P2Y12 and P2Y13 receptors in neuropathic pain rats Juan Niu†, Dujuan Huang†, Rui Zhou†, MingXia Yue, Tao Xu, Junna Yang, Li He, Hong Tian, XiaoHong Liu and Junwei Zeng* Abstract Background: More evidence suggests that dorsal spinal cord microglia is an important site contributing to CB2 receptor-mediated analgesia. The upregulation of P2Y12 and P2Y13 purinoceptors in spinal dorsal horn microglia is involved in the development of pain behavior caused by peripheral nerve injury. However, it is not known whether the expression of P2Y12 and P2Y13 receptors at spinal dorsal horn will be influenced after CB2 receptor activation in neuropathic pain rats. Methods: Chronic constriction injury (CCI) and intrathecal ADPbetaS injection were performed in rats to induce neuropathic pain. The paw withdrawal latency (PWL) was used to evaluate thermal hyperalgesia in neuropathic rats. The expression of P2Y12 and P2Y13 receptors, p-p38MAPK, and NF-kappaBp65 was detected with RT-PCR and western blotting analysis. Results: Treatment with AM1241 produces a pronounced inhibition of CCI-induced thermal hyperalgesia and significantly inhibited the increased expression of P2Y12 and P2Y13 receptors at the mRNA and protein levels, which open up the possibility that P2Y12 and P2Y13 receptor expression are downregulated by CB2 receptor agonist AM1241 in CCI rats. Western blot analysis demonstrated that AM1241 reduced the elevated expression of p-p38MAPK and NF-κBp65 in the dorsal spinal cord induced by CCI. After administration with either SB203580 (p38MAPK inhibitor) or PDTC (NF-kappaB inhibitor), the levels of P2Y13 receptor expression in the dorsal spinal cord were lower than those in the CCI group.
    [Show full text]
  • The Expanded Endocannabinoid System/Endocannabinoidome As a Potential Target for Treating Diabetes Mellitus
    Current Diabetes Reports (2019) 19:117 https://doi.org/10.1007/s11892-019-1248-9 OBESITY (KM GADDE, SECTION EDITOR) The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus Alain Veilleux1,2,3 & Vincenzo Di Marzo1,2,3,4,5 & Cristoforo Silvestri3,4,5 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review The endocannabinoid (eCB) system, i.e. the receptors that respond to the psychoactive component of cannabis, their endogenous ligands and the ligand metabolic enzymes, is part of a larger family of lipid signals termed the endocannabinoidome (eCBome). We summarize recent discoveries of the roles that the eCBome plays within peripheral tissues in diabetes, and how it is being targeted, in an effort to develop novel therapeutics for the treatment of this increasingly prevalent disease. Recent Findings As with the eCB system, many eCBome members regulate several physiological processes, including energy intake and storage, glucose and lipid metabolism and pancreatic health, which contribute to the development of type 2 diabetes (T2D). Preclinical studies increasingly support the notion that targeting the eCBome may beneficially affect T2D. Summary The eCBome is implicated in T2D at several levels and in a variety of tissues, making this complex lipid signaling system a potential source of many potential therapeutics for the treatments for T2D. Keywords Endocannabinoidome . Bioactive lipids . Peripheral tissues . Glucose . Insulin Introduction: The Endocannabinoid System cannabis-derived natural product, Δ9-tetrahydrocannabinol and its Subsequent Expansion (THC), responsible for most of the psychotropic, euphoric to the “Endocannabinoidome” and appetite-stimulating actions (via CB1 receptors) and immune-modulatory effects (via CB2 receptors) of marijuana, The discovery of two G protein-coupled receptors, the canna- opened the way to the identification of the endocannabinoids binoid receptor type-1 (CB1) and − 2 (CB2) [1, 2], for the (eCBs).
    [Show full text]
  • Surname Fore-Names Date of Death Age Plot No ADAMS CHARLOTTE
    Surname Fore-Names Date of Death Age Plot No ADAMS CHARLOTTE 7 November 1885 47 L108 ADAMS ELLEN 22 June 1899 66 L108 ADAMS OLIVER 30 October 1912 77 L108 AHERNE ANNIE 09 February 1942 75 D421 AHERNE ELLEN 02 January 1989 97 D421 AHERNE JOHN 08 January 1927 63 D421 AIKEN HENRY 3 December 1872 46 L388 ALEXANDER ALICE ALICIA 20 January 1886 18 M187 ALEXANDER ELIZA 21 June 1886 70 L1378 ALEXANDER IVOR 17 August 1931 75 L1378 ALEXANDER JOHN 24 November 1895 60 M187 ALEXANDER JOHN DAVID 8 September 1876 0 M187 ALEXANDER MARY 02 March 1927 86 M187 ALEXANDER MARY ELIZA 4 January 1876 32 L1378 ALEXANDER PHILIP THOMAS LLEWELLYN 17 March 1886 0 L374/L395 ALEXANDER THOMAS 09 March 1904 47 L374/L395 ALEXANDER WILLIAM 20 October 1886 70 L1378 ALEXANDER WILLIAM THOMAS 15 August 1876 31 L1378 ALLEN ANN 19 October 1901 84 L1342 ALLEN CHARLES 17 August 1882 65 L1342 ALLEN HENRY 16 June 1876 61 L211 ALLEN MARY ANNE 30 January 1885 75 M439 ALLEN SAMUEL WESLEY 06 October 1920 74 M439 ALLEN SARAH 25 February 1900 81 L211 AMESBURY JAMES 14 September 1911 74 L2871 AMESBURY MARY 04 May 1923 56 L2871 ANDERSON ANNIE 08 January 1909 91 X535 ANDERSON WALTER 17 February 1921 90 X535 ANGEL ELLEN MARIA 14 December 1930 83 L971/L995 ANGEL SARAH 11 March 1898 79 L971/L995 ANGEL WILLIAM 26 January 1922 75 L971/L995 ANGEL WILLIAM 16 March 1898 83 L971/L995 ANGEL WILLIAM ALFRED EDWIN 8 October 1876 L971/L995 ANNING JOHN HENRY 21 Sept 1885 62 L920 ANSTEE HARRIETTE 13 February 1912 75 L1065 ANSTEE JOHN 4 May 1886 56 L1065 ARCH ANN 05 March 1907 62 L882 ARCH ESTHER L882 ARCH
    [Show full text]